Pharmaceutical Machinery Market German Manufacturers of Pharmaceutical Machinery Among Market Leaders

| Editor: Dominik Stephan

At the Interpack trade fair the German Association of machinery and industrial equipment manufacturers VDMA gave a brief outlook on the developement of the global market for pharmaceutical machinery manufacture industry. The VDMA expects future developement for producers of pharamaceutical machinery in the emerging countries.

Related Companies

The quality requirements in production and packaging technology are increasing. (Picture: Vetter Pharma International)
The quality requirements in production and packaging technology are increasing. (Picture: Vetter Pharma International)

Duesseldorf/Germany – The German pharmaceutical machinery manufacturers are among the global leaders of the market, as VDMA officials state at the Interpack trade fair. “The VDMA assesses the German production volume in pharmaceutical production and packaging machinery to around one and a half billion Euros,” explained Dr. Peter Golz, Deputy Managing Director of the Food Processing and Packaging Machinery Association. In value every fourth machine installed worldwide comes from German production.

Therefore the industry reckons good chances to profit from further worldwide investments, which are assessed to six or seven billion Euros by the VDMA. “The international pharmaceutical market is going through a radical change. Product mix and regional growth emphasizes are moving. Our sector will furthermore profit from that,” Golz emphasized.

Pharmaceutical Machinery Market requires flexible production Systems

Today’s production structures no longer meet future market requirements. Especially new agents that require sterile production and aseptic filling procedures are posing a challenge for pharmaceutical machinery manufacturers. “The research based industry has invested solid in the extension of capacities. The trend continues: The introduction of bio-generics causes additional capacity needs,” states Golz.

Furthermore, new treatments are often aimed at niche applications for which they offer additional therapeutic benefits compared to commercially available remedies. “The days of high volume business are obviously numbered for Big Pharma,” states Golz. “The market calls for flexible systems for small production lots and frequent product changes. That also meets the increased requirements of the new generation of highly efficient agents in terms of dispensing accuracy and operator protection.”